IC
IMNM icon

Ikarian Capital’s Immunome IMNM Stock Holding History

Ikarian Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
+60,000
New +$1.28M 0.14% 101

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Ikarian Capital's IMNM Position: Q2 2026 in Review

Ikarian Capital opened a new position in Immunome (IMNM) in Q2 2026: 60,000 shares worth $1.27M. The stake represents 0.14% of the portfolio and ranks #101 among its holdings.

202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Ikarian Capital held 60,000 shares of Immunome worth $1.27M as of Q2 2026.
  • Immunome was a new Ikarian Capital position in Q2 2026.
  • Immunome made up 0.14% of Ikarian Capital's portfolio in Q2 2026, its #101 holding.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.